Welcome to our dedicated page for Dss news (Ticker: DSS), a resource for investors and traders seeking the latest updates and insights on Dss stock.
DSS, Inc. reports developments across a diversified operating platform that includes Product Packaging, Biotechnology, Commercial Lending, and Securities & Investment Management. Company updates commonly address packaging operations, financial results, balance-sheet actions, common-stock offerings, and regulatory or audit disclosures.
News also covers subsidiary activity such as Sentinel Brokers Company, Inc., a FINRA-registered broker-dealer with fixed income trading, equity market-making, and approval to act as an underwriter and selling group member for corporate securities offerings.
Document Security Systems (DSS) has signed a $40 million subscription agreement with American Pacific Bancorp (APB) to acquire 6,666,700 shares at $6.00 each, making DSS a majority owner of APB. This investment aims to bolster APB's capacity for diversified lending, including mortgages and medical real estate financing. DSS anticipates quick deployment of this capital to generate interest before the end of 2021, highlighting a strong validation of APB's business model.
Document Security Systems (DSS) announced a significant investment of $15 million from Alset EHome International, which will see the issuance of 12,155,591 shares at $1.234 per share. This strategic partnership indicates strong confidence from Alset in DSS and aims to enhance growth opportunities for both entities. DSS operates across multiple sectors, including blockchain security and healthcare, and has a unique business model that allows shareholders to benefit from its subsidiary IPOs. CEO Frank D. Heuszel emphasized the mutual growth potential between the companies.
Impact BioMedical, a subsidiary of DSS, and GRDG Sciences have successfully synthesized their first Quantum-based compound aimed at enhancing immune response. This achievement follows over a year of research initiated in Summer 2020. The compound, designed to improve therapeutic efficacy and combat a projected patent cliff in the pharmaceutical industry, will undergo testing at a prominent university. The development of this compound, inspired by quantum mechanics, could potentially lead to significant medical breakthroughs and a new class of medicines.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced promising results from clinical tests of its 3FDB (DEET Booster) technology aimed at enhancing mosquito repellents. Conducted in collaboration with Global Research and Discovery Group (GRDG), the tests demonstrated significant improvement in mosquito repellency rates, outperforming DEET alone. The tests revealed a 98% repellency rate after 3 hours with a 10% 3FDB and 5% DEET mix. The results indicate potential applications in personal care products and underscore the technology's capability to address mosquito-borne diseases.
Document Security Systems, Inc. (DSS) promoted Todd D. Macko to Chief Financial Officer effective August 16, 2021. With over 25 years of public and corporate accounting experience, Macko previously served as Vice President of Finance at DSS. His expertise includes financial planning, budgeting, and mergers and acquisitions. CEO Frank D. Heuszel expressed confidence in Macko's ability to support the company's long-term strategy. DSS operates in multiple sectors including blockchain security and renewable energy, focusing on shareholder value through potential spin-offs of subsidiaries.
DSS, a multinational company, announced a $1 million equity investment in Vivacitas Oncology, a clinical-stage firm focused on difficult-to-treat cancers. This investment, made through DSS Biomedical, highlights DSS's commitment to enhancing human healthcare. Vivacitas's lead candidate, AR-67, shows promise in treating cancers resistant to current therapies, with clinical data indicating potential improvements in progression-free survival for glioblastoma patients while reducing severe side effects. The CEO of DSS expressed optimism about the strategic investment.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced a collaboration with Thomas Swan Co. to research Procombin, a plant-based preservation booster. This partnership aims to test Procombin's effectiveness in extending the shelf life of consumer products including personal care and cleaning items. Daryl Thompson emphasized the project’s potential to enhance product quality globally. Thomas Swan, established in 1926, specializes in custom chemical research. The development of Procombin represents a significant step towards sustainable preservation solutions.
Impact BioMedical, a subsidiary of Document Security Systems (NYSE American: DSS), announced the issuance of Patent # 11,033,528 for its antiviral compound Equivir on June 15, 2021. This patent follows the initial patent granted in 2019. Equivir has shown positive pre-clinical results against viral infections including Ebola and Rhinovirus. The company is pursuing a third patent and aims to explore its potential in various antiviral applications, enhancing its intellectual property portfolio.
Impact Biomedical, a subsidiary of Document Security Systems (DSS), announced major updates on its research projects aimed at addressing global challenges in biotechnology. Key collaborations and advancements were highlighted, including the Procombin study to improve antibiotics and the CRST-1 molecule, which shows promising results in cancer treatment. The company is also exploring global licensing for several products, such as Equivir and Linebacker. This strategic focus on innovation positions Impact Biomedical as a potential leader in the biotech industry.
Document Security Systems (DSS) announced the launch of Liquid Value Asset Management Limited (LVAM) through its subsidiary, DSS Financial Management Inc. This fund management company, based in Hong Kong, will focus on algorithmic trading across various financial instruments. The team, including former Societe Generale and Citadel professionals, boasts a track record of 20% annual returns and a Sharpe ratio above 2.0. CEO Frank D. Heuszel expressed confidence in rapidly growing LVAM's trading assets to over $1 billion.